BRAF and cancer: This is supported by the absence of pyroptosis-related markers in BRAF and MEK-combined inhibition-resistant BRAF-mutant cancer models, which was associated with reduced T cell antitumor immunity and, importantly, was sensitive to pyroptosis-inducing chemotherapy [152].